Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is sold both by itself and in combination as efavirenz/emtricitabine/tenofovir. It is taken by mouth once a day.
|Trade names||Sustiva, others|
|By mouth (capsules, tablets)|
|Bioavailability||40–45% (under fasting conditions)|
|Metabolism||Hepatic (CYP2A6 and CYP2B6-mediated)|
|Onset of action||3–5 hours|
|Elimination half-life||40–55 hours|
|Excretion||Urine (14–34%) and feces (16–61%)|
|CompTox Dashboard (EPA)|
|ECHA InfoCard||100.149.346 |
|Chemical and physical data|
|Molar mass||315.675 g/mol g·mol−1|
|3D model (JSmol)|
Common side effects include rash, nausea, headache, feeling tired, and trouble sleeping. Some of the rashes may be serious such as Stevens-Johnson syndrome. Other serious side effects include depression, thoughts of suicide, liver problems, and seizures. It is not safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.
Efavirenz was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2015 it is not available as a generic medication. The wholesale cost in the developing world is about US$3.27 to 9.15 per month. As of 2015 the cost for a typical month of medication in the United States is more than US$200.
For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines recommends the use of efavirenz in combination with tenofovir/emtricitabine (Truvada) as one of the preferred NNRTI-based regimens in adults and adolescents and children.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded post-exposure prophylaxis regimen to reduce the risk of HIV infection in people exposed to a significant risk (e.g. needlestick injuries, certain types of unprotected sex, etc.).
People who have taken this medication before and experienced an allergic reaction should avoid taking further efavirenz dosages. Hypersensitivity reactions include Steven-Johnson syndrome, toxic skin eruptions, and erythema multiforme.
Neuropsychiatric effects are the most common adverse effects, and include disturbed sleep (including nightmares, insomnia, disrupted sleep, and daytime fatigue), dizziness, headaches, vertigo, blurred vision, anxiety, and cognitive impairment (including fatigue, confusion, and memory and concentration problems), and depression, including suicidal thinking. Some people experience euphoria.
Efavirenz may cause convulsions in adult and pediatric populations who have a history of seizures.
Efavirenz is broken down in the liver by enzymes that belong to the cytochrome P450 system, which include both CYP2B6 and CYP3A4. Efavirenz is a substrate of these enzymes and can decrease the metabolism of other drugs that require the same enzymes. However, efavirenz also induces these enzymes, which means the enzyme activity is enhanced and the metabolism of other drugs broken down by CYP2B6 and CYP3A4 can be increased. People who are taking both efavirenz and other drugs metabolized by the same enzymes might need the dose of their drugs to be increased or decreased.
One group of drugs that efavirenz affects is protease inhibitors, which are used for HIV/AIDS. Efavirenz will lower the blood levels of most protease inhibitors, including aprenavir, atazanavir, and indinavir. At lowered levels, protease inhibitors may not be effective in people taking both drugs, which means the virus that causes HIV/AIDS won’t be stopped from replicating and may become resistant to the protease inhibitor.
Efavirenz also affects antifungal drugs, which are used for fungal infections such as urinary tract infections. Similar to the effect seen with protease inhibitors, efavirenz lowers the blood levels of antifungal drugs like voriconazole, itraconazole, ketoconazole, and posaconazole. As a result of lowered levels, antifungal drugs may not be effective in people taking both drugs, which means that the fungi that cause the infection may become resistant to the antifungal.
Mechanism of action
Efavirenz falls in the NNRTI class of antiretrovirals. Both nucleoside and non-nucleoside RTIs inhibit the same target, the reverse transcriptase enzyme, an essential viral enzyme which transcribes viral RNA into DNA. Unlike nucleoside RTIs, which bind at the enzyme's active site, NNRTIs act allosterically by binding to a distinct site away from the active site known as the NNRTI pocket.
As most NNRTIs bind within the same pocket, viral strains which are resistant to efavirenz are usually also resistant to the other NNRTIs, nevirapine and delavirdine. The most common mutation observed after efavirenz treatment is K103N, which is also observed with other NNRTIs. Nucleoside reverse-transcriptase inhibitors (NRTIs) and efavirenz have different binding targets, so cross-resistance is unlikely; the same is true with regard to efavirenz and protease inhibitors.
As of 2016 the mechanism of efavirenz' neuropsychiatric adverse effects was not clear. Efavirenz appears to have neurotoxicity, possibly by interfering with mitochondrial function, which may in turn possibly be caused by inhibiting creatine kinase but also possibly by disrupting mitochondrial membranes or by interfering with nitric oxide signalling. Some neuropsychiatric adverse effects may be mediated through cannabinoid receptors, or through activity at the 5-HT2A receptor, but efavirenz interacts with many CNS receptors, so this is not clear. The neuropsychiatric adverse effects are dose-dependent.
Efavirenz is chemically described as (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is C14H9ClF3NO2. Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68 g/mol. It is practically insoluble in water (<10 µg/mL).
Efavirenz was approved by the FDA on September 21, 1998, making it the 14th approved antiretroviral drug.
On February 17, 2016, the FDA approved the generic tablet formulation to be produced by Mylan.
In late-2018, Thailand's Government Pharmaceutical Organization (GPO) announced that it will produce efavirenz after receiving WHO approval. Efavirenz code name is DMP 266, discovered by Du pont Pharma. European countries are set to receive the license for manufacturing of Efavirenz in May 1999.
Society and culture
A one-month supply of 600 mg tablets costs approximately US$1,010 in July 2016. In 2007, Merck provided Efavirenz in certain developing countries and countries largely affected by HIV for about US$0.65 per day. Some emerging countries have opted to purchase Indian generics.
In Thailand, a one month supply of efavirenz + Truvada, as of June 2012, cost 2,900 baht (US$90), and there is a social program for patients who cannot afford the medication. As of 2018 Thailand will produce efavirenz domestically. Its Government Pharmaceutical Organization product costs 180 baht per bottle of thirty 600 mg tablets. The imported version in Thailand retails for more than 1,000 baht per bottle. GPO will devote 2.5 percent of its manufacturing capacity to make 42 million efavirenz pills in 2018, allowing it to serve export markets as well as domestic. The Philippines alone will order about 300,000 bottles of efavirenz for 51 million baht.
Abuse of efavirenz by crushing and smoking the tablets for supposed hallucinogenic and dissociative effects has been reported in South Africa, where it is used in a mixture known as whoonga and nyaope.
As of 2016, efavirenz was marketed in various jurisdictions under the brand names Adiva, Avifanz, Efamat, Efatec, Efavir, Efavirenz, Efcure, Eferven, Efrin, Erige, Estiva, Evirenz, Filginase, Stocrin, Sulfina V, Sustiva, Virorrever, and Zuletel.
As of 2016, the combination of efavirenz, tenofovir, and emtricitabine was marketed in various jurisdictions under the brand names Atripla, Atroiza, Citenvir, Oditec, Teevir, Trustiva, Viraday, and Vonavir.
As of 2016, the combination of efavirenz, tenofovir, and lamivudine was marketed under the brand name Eflaten.
- "Efavirenz". The American Society of Health-System Pharmacists. Archived from the original on 17 November 2016. Retrieved 28 November 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 62. ISBN 9781284057560.
- "Efavirenz". International Drug Price Indicator Guide. Retrieved 28 November 2016.
- "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents". July 14, 2016. Archived from the original on May 23, 2013.
- "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection". NIH AIDSinfo. March 1, 2016. Archived from the original on November 15, 2016.
- Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis". Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. PMID 23917901.
- "Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States =" (PDF). Centers for Disease Control and Prevention. Archived (PDF) from the original on January 27, 2017. Retrieved November 7, 2016.
- Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, et al. (March 2014). "Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis". AIDS. 28 Suppl 2: S123–31. doi:10.1097/qad.0000000000000231. PMID 24849471.
- Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ (July 2015). "Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies". The Journal of Antimicrobial Chemotherapy. 70 (7): 1928–41. doi:10.1093/jac/dkv080. PMC 4472329. PMID 25858354.
- "Efavirenz label" (PDF). FDA. October 2016. Archived (PDF) from the original on 2016-11-10.
- Treisman GJ, Soudry O (October 2016). "Neuropsychiatric Effects of HIV Antiviral Medications". Drug Safety. 39 (10): 945–57. doi:10.1007/s40264-016-0440-y. PMID 27534750.
- Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV (October 2015). "Efavirenz and the CNS: what we already know and questions that need to be answered". The Journal of Antimicrobial Chemotherapy. 70 (10): 2693–708. doi:10.1093/jac/dkv183. PMID 26203180.
- Rossi S, Yaksh T, Bentley H, van den Brande G, Grant I, Ellis R (May 2006). "Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine". Clinical Chemistry. 52 (5): 896–7. doi:10.1373/clinchem.2006.067058. PMID 16638958.
- Röder CS, Heinrich T, Gehrig AK, Mikus G (June 2007). "Misleading results of screening for illicit drugs during efavirenz treatment". AIDS. 21 (10): 1390–1. doi:10.1097/QAD.0b013e32814e6b3e. PMID 17545727.
- Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, et al. (October 2016). "Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers". Journal of Cardiovascular Electrophysiology. 27 (10): 1206–1213. doi:10.1111/jce.13032. PMC 5065384. PMID 27333947.
- Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK (October 2002). "Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors". Proceedings of the National Academy of Sciences of the United States of America. 99 (22): 14410–5. doi:10.1073/pnas.222366699. PMC 137897. PMID 12386343.
- "Efavirenz Drug Profile". DrugPatentWatch. Archived from the original on 2016-11-10. Retrieved 2016-11-09.
- Wipatayotin, Apinya (3 November 2018). "Thailand gets nod to make HIV/Aids drug". Bangkok Post. Retrieved 3 November 2018.
- "Efavirenz (Sustiva)". aidsmap. June 2017.
- "Cost Considerations and Antiretroviral Therapy | Adult and Adolescent ARV Guidelines | AIDSinfo". AIDSinfo. Archived from the original on 2016-11-17. Retrieved 2016-11-16.
- "Merck & Co., Inc., Again Reduces Price of Stocrin (Efavirenz) for Patients in Least Developed Countries and Countries Hardest Hit by Epidemic". Drugs.com MedNews. Archived from the original on 2014-07-14.
- IndiaDaily - A new trend in emerging nations - Brazil opts for Indian generic drug ignoring US pharmaceutical giant Merck's patent on AIDS drug Efavirenz Archived 2008-02-19 at the Wayback Machine
- Osewe PL, Korkoi Nkrumah Y, Sackey EK (15 June 2008). Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property Rights (TRIPS) Flexibilities Utilization. World Bank Publications. pp. 35–39. ISBN 978-0-8213-7544-0. Retrieved 30 June 2012.
- IOL: Thugs get high on stolen Aids drugs Archived 2013-08-06 at the Wayback Machine IOL News May 12, 2007
- Getting high on HIV drugs in S Africa. BBC News, 8 December 2008. Archived 9 December 2008 at the Wayback Machine
- 'No Turning Back': Teens Abuse HIV Drugs. ABC News, April 6, 2009. Archived April 8, 2009, at the Wayback Machine
- Getting High On HIV Medication Archived 2014-04-11 at the Wayback Machine Vice 7.04.2014.
- "International brands for Efavirenz". Drugs.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.